1. Name Of The Medicinal Product
Beconase Aqueous Nasal Spray
2. Qualitative And Quantitative Composition
Beclometasone Dipropionate 50μg (as monohydrate, micronised)
3. Pharmaceutical Form
Aqueous suspension for intranasal inhalation via metered dose atomising pump.
4. Clinical Particulars
4.1 Therapeutic Indications
Beconase Aqueous Nasal Spray is indicated for the prophylaxis and treatment of perennial and seasonal allergic rhinitis including hayfever, and vasomotor rhinitis. Beclometasone dipropionate has a potent anti-inflammatory effect within the respiratory tract, with a lower incidence and severity of adverse events than those observed when corticosteroids are administered systemically.
4.2 Posology And Method Of Administration
Beconase Aqueous Nasal Spray is for administration by the intranasal route only.
Adults and children over six years of age:
The recommended dosage is two sprays into each nostril twice daily (400 micrograms/day). Once control has been established it may be possible to maintain control with fewer sprays. A dosage regimen of one spray into each nostril morning and evening has been shown to be efficacious in some patients. However, should symptoms recur, patients should revert to the recommended dosage of two sprays into each nostril morning and evening. The minimum dose should be used at which effective control of symptoms is maintained. Total daily administration should not normally exceed eight sprays.
For full therapeutic benefit regular usage is essential. The co-operation of the patient should be sought to comply with the regular dosage schedule and it should be explained that maximum relief may not be obtained within the first few applications.
For children under six years old, there are insufficient clinical data to recommend use.
4.3 Contraindications
Beconase Aqueous Nasal Spray is contra-indicated in patients with a history of hypersensitivity to any of its components.
4.4 Special Warnings And Precautions For Use
Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Growth retardation has been reported in children receiving nasal corticosteroids at licensed doses.
It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid, if possible to the lowest dose at which effective control of symptoms is maintained. In addition, consideration should be given to referring the patient to a paediatric specialist.
Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Care must be taken while transferring patients from systemic steroid treatment to Beconase Aqueous Nasal Spray if there is any reason to suppose that their adrenal function is impaired.
Infections of the nasal passages and paranasal sinuses should be appropriately treated but do not constitute a specific contra-indication to treatment with Beconase Aqueous Nasal Spray.
Although Beconase Aqueous Nasal Spray will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may in certain instances necessitate appropriate additional therapy particularly to control eye symptoms.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Not applicable
4.6 Pregnancy And Lactation
There is inadequate evidence of safety in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. It should be noted, however, that the foetal changes in animals occur after relatively high systemic exposure. Beconase Aqueous Nasal Spray delivers beclometasone dipropionate directly to the nasal mucosa and so minimises systemic exposure.
The use of beclometasone dipropionate should be avoided during pregnancy unless thought essential by the doctor.
No specific studies examining the transference of beclometasone dipropionate into the milk of lactating animals have been performed. It is reasonable to assume that beclometasone dipropionate is secreted in milk but at the dosages used for direct intranasal administration there is low potential for significant levels in breast milk. The use of beclometasone dipropionate in mothers breast feeding their babies requires that the therapeutic benefits of the drug be weighed against the potential hazards to the mother and baby.
4.7 Effects On Ability To Drive And Use Machines
Not applicable
4.8 Undesirable Effects
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (
|
|
|
|
|
|
|
| |
|
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
|
|
|
As with other nasal sprays, dryness and irritation of the nose and throat, and epistaxis have been reported. Nasal septal perforation has also been reported following the use of intranasal corticosteroids.
Systemic effects of nasal corticosteroids may occur particularly when used at high doses for prolonged periods.
4.9 Overdose
The only harmful effect that follows inhalation of large amounts of the drug over a short time period is suppression of Hypothalamic-Pituitary-Adrenal (HPA) function. No special emergency action need be taken. Treatment with Beconase Aqueous Nasal Spray should be continued at the recommended dose. HPA function recovers in a day or two.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Following topical administration beclometasone 17,21-dipropionate (BDP) produces potent anti-inflammatory and vasoconstrictor effects.
BDP is a pro-drug with weak corticosteroid receptor binding affinity. It is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate (B-17-MP), which has high topical anti-inflammatory activity.
Beclometasone dipropionate offers a preventative background treatment for hayfever when taken prior to allergen challenge. After which with regular use, BDP can continue to prevent allergy symptoms from reappearing.
5.2 Pharmacokinetic Properties
Absorption
Following intranasal administration of BDP in healthy males, the systemic absorption was assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following intranasal administration is 44% (95% CI 28%, 70%). After intranasal administration, <1% of the dose is absorbed by the nasal mucosa. The remainder after being cleared from the nose, either by drainage or mucocilary clearance, is available for absorption from the gastrointestinal tract. Plasma B-17-MP is almost entirely due to conversion of BDP absorbed from the swallowed dose.
Following oral administration of BDP in healthy males, the systemic absorption was also assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following oral administration is 41% (95% CI 27%, 62%).
Following an oral dose, B-17-MP is absorbed slowly with peak plasma levels reached 3-5 hours after dosing.
Metabolism
BDP is cleared very rapidly from the circulation and plasma concentrations are undetectable (< 50pg/ml) following oral or intranasal dosing. There is rapid metabolism of the majority of the swallowed portion of BDP during its first passage through the liver. The main product of metabolism is the active metabolite (B-17-MP). Minor inactive metabolites, beclometasone-21-monopropionate (B-21-MP) and beclometasone (BOH), are also formed but these contribute little to systemic exposure.
Distribution
The tissue distribution at steady-state for BDP is moderate (20l) but more extensive for B-17-MP (424l). Plasma protein binding of BDP is moderately high (87%).
Elimination
The elimination of BDP and B-17-MP are characterised by high plasma clearance (150 and 120l/h) with corresponding terminal elimination half-lives of 0.5h and 2.7h. Following oral administration of tritiated BDP, approximately 60% of the dose was excreted in the faeces within 96 hours mainly as free and conjugated polar metabolites. Approximately 12% of the dose was excreted as free and conjugated polar metabolites in the urine.
5.3 Preclinical Safety Data
No clinically relevant findings were observed in preclinical studies.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Avicel RC 591 (Microcrystalline Cellulose And Carboxymethylcellulose Sodium) US NF
Anhydrous Dextrose BP
Benzalkonium Chloride BP
Phenylethyl Alcohol USP
Polysorbate 80 BP
Purified Water BP
6.2 Incompatibilities
Not applicable
6.3 Shelf Life
24 months when not stored above 30°C
6.4 Special Precautions For Storage
Beconase Aqueous Nasal Spray should not be stored above 30°C. Keepcontainer in the outer carton. Do not refrigerate.
6.5 Nature And Contents Of Container
A 25ml amber neutral glass bottle fitted with a metering atomising pump, or a 30ml polypropylene bottle fitted with a tamper-resistant metering atomising pump. The pumps are manufactured by: Valois S.A. Le Prieure BPG, 27110 Le Neubourg, France.
Pack size: 200 Metered Spray.
6.6 Special Precautions For Disposal And Other Handling
Refer to Patient Information Leaflet.
Administrative Data
7. Marketing Authorisation Holder
Glaxo Wellcome UK Ltd.
Trading as Allen and Hanburys,
Stockley Park West,
Uxbridge
Middlesex, UB11 1BT
8. Marketing Authorisation Number(S)
PL 10949/0104
9. Date Of First Authorisation/Renewal Of The Authorisation
12th April 2003
10. Date Of Revision Of The Text
26 January 2006
11. Legal Status
POM
No comments:
Post a Comment